IPP Bureau
FDA grants priority review to Bristol Myers Squibb's Iberdomide for multiple myeloma
By IPP Bureau - February 17, 2026
Iberdomide has the potential to be the first approved CELMoD agent
Roche appoints Mark Dawson as new Head of Pharma Research and Early Development
By IPP Bureau - February 17, 2026
Dawson joins Roche from the Peter MacCallum Cancer Centre, where he serves as Associate Director of Research
Indian pharma market grew 10.2% yoy in January 2026
By IPP Bureau - February 17, 2026
Ind-Ra expects chronic therapies to outpace IPM as compliance improves and lifestyle diseases rise
Biofrontera scores FDA filing acceptance for Ameluz PDT in skin cancer breakthrough
By IPP Bureau - February 16, 2026
If approved, Ameluz would become the first and only photodynamic therapy (PDT) photosensitizer for sBCC in the US
Dewpoint Therapeutics selects groundbreaking MYC development candidate
By IPP Bureau - February 16, 2026
MYC, a master regulator of oncogenic transcription, drives multiple high-burden cancers but has long eluded direct pharmacologic control
STADA & Bio-Thera bag European nod for Gotenfia
By IPP Bureau - February 16, 2026
Clinigen bags Japan's nod to human milk-based medicine for preterm infants
By IPP Bureau - February 16, 2026
PreemieFort Enteral Solution's approval marks the first time a nutritional product derived from human milk has been recognized as a prescription medicine anywhere in the world
Amgen scores EU nod for UPLIZNA in rare autoimmune disease
By IPP Bureau - February 16, 2026
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
Lundbeck’s bocunebart shows breakthrough potential in migraine prevention
By IPP Bureau - February 16, 2026
Bocunebart works by blocking pituitary adenylate cyclase-activating polypeptide
BridgeBio reports breakthrough results in Phase 3 achondroplasia trial
By IPP Bureau - February 16, 2026
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
Lyell Immunopharma launches groundbreaking Phase 3 CAR T-Cell trial for aggressive lymphoma
By IPP Bureau - February 16, 2026
PiNACLE is a head-to-head study comparing its next-generation CAR T-cell therapy against established therapies liso-cel and axi-cel in patients with relapsed or refractory large B-cell lymphoma
Centivax launches first human trial of universal flu vaccine
By IPP Bureau - February 16, 2026
Agilent’s PD-L1 test gains FDA nod for ovarian cancer
By IPP Bureau - February 16, 2026
This approval represents the seventh FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx with KEYTRUDA
NATCO receives CDSCO approval for Semaglutide in India
By IPP Bureau - February 15, 2026
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus
